SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
1-Year Return
40.04%
This Quarter Return
+8.55%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$102M
AUM Growth
-$1.25M
(-1.2%)
Cap. Flow
-$3.93M
Cap. Flow
% of AUM
-3.88%
Top 10 Holdings %
Top 10 Hldgs %
59.23%
Holding
86
New
20
Increased
24
Reduced
14
Closed
28
Top Buys
| 1 |
Verastem
VSTM
|
+$3.1M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$2.84M |
| 3 |
Ardelyx
ARDX
|
+$2.18M |
| 4 |
ITOS
iTeos Therapeutics
ITOS
|
+$1.99M |
| 5 |
Nektar Therapeutics
NKTR
|
+$1.3M |
Top Sells
| 1 |
OPTN
OptiNose
OPTN
|
+$7.23M |
| 2 |
UroGen Pharma
URGN
|
+$3.69M |
| 3 |
Aquestive Therapeutics
AQST
|
+$3.04M |
| 4 |
Establishment Labs
ESTA
|
+$2.88M |
| 5 |
Galapagos
GLPG
|
+$2.36M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ADMA Biologics
ADMA
$3.84B
| $13.7M | 13.4% |
750,000
-60,000
| -7% | -$1.09M |
|
2
Evolus
EOLS
$465M
| $8.44M | 8.28% |
916,500
-218,074
| -19% | -$2.01M |
|
3
Zevra Therapeutics
ZVRA
$435M
| $6.83M | 6.7% |
775,620
+125,620
| +19% | +$1.11M |
|
|
4
Verastem
VSTM
$598M
| $5.65M | 5.54% |
1,360,386
+747,386
| +122% | +$3.1M |
|
5
Indivior
INDV
$2.9B
| $5.16M | 5.06% |
350,000
+46,000
| +15% | +$678K |
|
|
6
Acadia Pharmaceuticals
ACAD
$3.98B
| $4.85M | 4.76% |
225,000
+131,607
| +141% | +$2.84M |
|
7
Enanta Pharmaceuticals
ENTA
$177M
| $4.57M | 4.48% |
604,066
+13,324
| +2% | +$101K |
|
8
TELA Bio
TELA
$62.6M
| $4.04M | 3.97% |
2,083,762
+28,537
| +1% | +$55.4K |
|
9
Xoma
XOMA
$452M
| $3.83M | 3.76% |
152,143
+22,330
| +17% | +$563K |
|
|
ITOS
10
DELISTED
iTeos Therapeutics
ITOS
| $3.09M | 3.03% |
310,033
+200,033
| +182% | +$1.99M |
|
11
Day One Biopharmaceuticals
DAWN
$729M
| $2.93M | 2.87% |
450,000
+101,180
| +29% | +$658K |
|
12
Surrozen
SRZN
$99.2M
| $2.74M | 2.68% |
306,029
+20,247
| +7% | +$181K |
|
13
ANI Pharmaceuticals
ANIP
$2.12B
| $2.52M | 2.47% |
38,597
-9,403
| -20% | -$614K |
|
|
14
Ardelyx
ARDX
$1.59B
| $2.18M | 2.13% |
+555,000
| New | +$2.18M |
|
15
Anika Therapeutics
ANIK
$125M
| $2.02M | 1.98% |
190,590
-16,049
| -8% | -$170K |
|
16
AYTU BioPharma
AYTU
$21.2M
| $1.77M | 1.74% |
812,676
+348,955
| +75% | +$761K |
|
17
Inhibikase Therapeutics
IKT
$116M
| $1.43M | 1.4% |
733,793
-181,180
| -20% | -$353K |
|
18
Geron
GERN
$810M
| $1.41M | 1.38% |
1,000,000
+500,000
| +100% | +$705K |
|
19
Heron Therapeutics
HRTX
$193M
| $1.36M | 1.34% |
657,380
-138,720
| -17% | -$287K |
|
|
20
Nektar Therapeutics
NKTR
$926M
| $1.3M | 1.27% |
+50,200
| New | +$1.3M |
|
21
Y-mAbs Therapeutics
YMAB
$390M
| $1.29M | 1.26% |
285,300
+154,140
| +118% | +$695K |
|
22
Collegium Pharmaceutical
COLL
$1.18B
| $1.23M | 1.2% |
41,500
+20,893
| +101% | +$618K |
|
23
Vanda Pharmaceuticals
VNDA
$266M
| $1.18M | 1.16% |
250,000
+214,852
| +611% | +$1.01M |
|
24
KalVista Pharmaceuticals
KALV
$708M
| $1.13M | 1.11% |
100,000
+78,450
| +364% | +$887K |
|
|
ALMS
25
Alumis Inc. Common Stock
ALMS
$455M
| $1.05M | 1.03% |
+349,615
| New | +$1.05M |
|